PI3K Isoform Inhibition Associated with Anti Bcr-Abl Drugs Shows in Vitro Increased Anti-leukemic Activity in Philadelphia Chromosome-positive B-acute Lymphoblastic Leukemia Cell Lines
McCubrey, James A.. (February 2017).
PI3K Isoform Inhibition Associated with Anti Bcr-Abl Drugs Shows in Vitro Increased Anti-leukemic Activity in Philadelphia Chromosome-positive B-acute Lymphoblastic Leukemia Cell Lines.
Oncotarget,
(8:14), p.23213-23227. Retrieved from
http://hdl.handle.net/10342/9623
McCubrey, James A..
"PI3K Isoform Inhibition Associated with Anti Bcr-Abl Drugs Shows in Vitro Increased Anti-leukemic Activity in Philadelphia Chromosome-positive B-acute Lymphoblastic Leukemia Cell Lines". Oncotarget.
8:14. (23213-23227.),
February 2017.
May 24, 2022.
http://hdl.handle.net/10342/9623.
Chicago:
McCubrey, James A.,
"PI3K Isoform Inhibition Associated with Anti Bcr-Abl Drugs Shows in Vitro Increased Anti-leukemic Activity in Philadelphia Chromosome-positive B-acute Lymphoblastic Leukemia Cell Lines," Oncotarget 8, no.
14 (February 2017),
http://hdl.handle.net/10342/9623 (accessed
May 24, 2022).
AMA:
McCubrey, James A..
PI3K Isoform Inhibition Associated with Anti Bcr-Abl Drugs Shows in Vitro Increased Anti-leukemic Activity in Philadelphia Chromosome-positive B-acute Lymphoblastic Leukemia Cell Lines. Oncotarget.
February 2017;
8(14)
23213-23227. http://hdl.handle.net/10342/9623. Accessed
May 24, 2022.
